P. Buhl-Jensen

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

Nicola Steele, Jane A. Plumb, Laura Vidal et al. · Clinical Cancer Research · 2008 · 243 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

Peter Gimsing, Mads Hansen, Lene Meldgaard Knudsen et al. · European Journal Of Haematology · 2008 · 161 citations

Medicine, Oncology, Pharmacology +8

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

Ulrik Lassen, L. Rhoda Molife, Engelholm Sa et al. · British Journal of Cancer · 2010 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Nicola Steele, Jane A. Plumb, Laura Vidal et al. · Cancer Chemotherapy and Pharmacology · 2010 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Indication of a role of plasminogen activator inhibitor type 1 in protecting murine fibrosarcoma cells against apoptosis

Maria Unni Rømer, A.K. Due, Jørgen K. Larsen et al. · Thrombosis and Haemostasis · 2005 · 22 citations

Medicine, Cancer Biology, Oncology +13